Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism

Area of Science:

• Pharmacology
• Neuroscience
• Addiction Medicine

Background:

• Endogenous enkephalins modulate pain and reward pathways.
• Dual inhibitors of enkephalin degrading enzymes, like RB 101, enhance enkephalinergic signaling.
• CCKB receptors play a role in modulating opioid effects.

Purpose of the Study:

• To investigate the effects of RB 101 on spontaneous morphine withdrawal and maintenance treatment in rats.
• To evaluate RB 101 alone and in combination with a CCKB antagonist (PD-134,308).
• To assess the potential of RB 101 as a substitutive treatment for opiate addiction.

Main Methods:

• Rats underwent chronic morphine treatment followed by 5-day maintenance with methadone, clonidine, RB 101, PD-134,308, or RB 101 + PD-134,308.
• Behavioral observations were conducted to assess acute effects and maintenance consequences on spontaneous withdrawal.
• Naloxone challenge was used to evaluate physical opiate dependence at the end of treatment.

Main Results:

• Methadone was most effective in reducing acute spontaneous withdrawal.
• Both methadone and RB 101 showed similar effectiveness in reducing opiate abstinence during maintenance.
• PD-134,308 had no effect alone or when combined with RB 101.
• RB 101 and methadone did not induce significant physical opiate dependence.

Conclusions:

• RB 101 effectively reduces opiate abstinence during maintenance treatment.
• RB 101 exhibits mild side effects, suggesting potential for opiate addiction treatment.
• Systemic inhibitors of enkephalin catabolism show promise for opiate addiction maintenance therapy.